RARE
Ultragenyx Pharmaceutical Inc. · Healthcare · Market cap $1.6B
Insiders sold $292K net in the last 90 days ·3 sellers, 0 buyers· latest Form 4 filed Oct 19, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.8M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Latest filing
Oct 19, 2026
Horn Howard
Ultragenyx Pharmaceutical Inc. (RARE) has 40 SEC Form 4 filings (52 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Oct 19, 2026.
Inside the rolling window, 9 insiders at Ultragenyx Pharmaceutical Inc. reported no open-market purchases and 27 open-market sales totaling $3.8M. The most active filer is Chief Financial Officer Horn Howard with 11 filings. Insiders have net sold $924K over the trailing 6 months. The most recent open-market filing is a sale of 7,066 shares by Chief Financial Officer Horn Howard, dated Oct 15, 2026, worth $108K.
- Industry:Biotechnology
- CEO:Emil D. Kakkis
- Employees:1,371
- HQ:Novato, CA, US
- IPO:2014-01-31
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 7,066 | $108K | Oct 19 | +5.6% | SEC ↗ | |
| SVP, Chief Accounting Officer | Sale | 1,283 | $17K | Sep 15 | +21.8% | SEC ↗ | |
Huizenga Theodore AlanFirst in 6 months | SVP, Chief Accounting Officer | Sale | 161 | $2K | Sep 8 | +7.0% | SEC ↗ |
| EVP and Chief Legal Officer | Sale | 1,900 | $47K | Aug 4 | -38.3% | SEC ↗ | |
| Chief Financial Officer | Sale | 4,696 | $117K | Aug 4 | -38.3% | SEC ↗ | |
| Chief Financial Officer | Sale | 4,698 | $156K | Jul 6 | -52.8% | SEC ↗ | |
| Director | Sale | 2,000 | $50K | Jun 15 | -37.3% | SEC ↗ | |
Parschauer Karah HerdmanFirst in 3 months | EVP and Chief Legal Officer | Sale | 1,899 | $47K | Jun 15 | -37.3% | SEC ↗ |
| Chief Financial Officer | Sale | 4,653 | $111K | Jun 1 | -30.3% | SEC ↗ | |
SULIMAN SHEHNAAZFirst filing | Director | Sale | 5,740 | $144K | May 18 | -34.2% | SEC ↗ |
| EVP and Chief Medical Officer | Sale | 344 | $9K | May 6 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 4,683 | $117K | May 4 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 4,683 | $98K | Apr 2 | — | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 6,018 | $129K | Mar 10 | — | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 3,508 | $80K | Mar 10 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 8,409 | $191K | Mar 3 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 1,635 | $37K | Mar 3 | — | SEC ↗ | |
Pinion John RichardFirst filing | See Remarks | Sale | 10,029 | $229K | Mar 3 | — | SEC ↗ |
| SVP, Chief Accounting Officer | Sale | 1,632 | $37K | Mar 3 | — | SEC ↗ | |
Harris ErikFirst filing | EVP & Chief Commercial Officer | Sale | 10,539 | $240K | Mar 3 | — | SEC ↗ |
KAKKIS EMIL DFirst filing | President & CEO | Sale | 54,404 | $1.2M | Mar 3 | — | SEC ↗ |
Parschauer Karah HerdmanFirst filing | EVP and Chief Legal Officer | Sale | 8,135 | $185K | Mar 3 | — | SEC ↗ |
| EVP and Chief Medical Officer | Sale | 7,029 | $160K | Mar 3 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 3,061 | $72K | Feb 3 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 3,150 | $72K | Jan 5 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading RARE 8 all-time
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-02-18
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002025-08-08
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002025-08-08
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002025-08-08
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002025-07-15
- DRep. Ro KhannaSale$1,001 - $15,0002022-01-21
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does RARE have?
Ultragenyx Pharmaceutical Inc. (RARE) has 40 SEC Form 4 filings (52 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Oct 19, 2026.
When was the most recent SEC Form 4 filing for RARE?
The most recent Form 4 filing for RARE on Tracefour is dated Oct 19, 2026.
Who is the most active insider at RARE?
The most active SEC Form 4 filer at RARE in the rolling window is Chief Financial Officer Horn Howard, with 11 filings.
What is the net insider flow at RARE over the last 6 months?
Over the trailing 180 days, insiders at RARE have net sold $924K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RARE in the current window?
Inside the rolling window, insiders at RARE bought $0 and sold $3.8M based on SEC Form 4 filings.
Can I get alerts for RARE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Ultragenyx Pharmaceutical Inc. (RARE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Ultragenyx Pharmaceutical Inc. is in the Healthcare sector.